Bio-Connect
All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.
All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.
All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.

Anti-PFKFB3 Monoclonal Antibody

M02382
Boster Bio
ApplicationsFlow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry
Product group Antibodies
TargetPFKFB3
100 ul
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Boster Bio
  • Product Name
    Anti-PFKFB3 Monoclonal Antibody
  • Delivery Days Customer
    9
  • Applications
    Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    ADII-16
  • Gene ID5209
  • Target name
    PFKFB3
  • Target description
    6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
  • Target synonyms
    IPFK2, PFK2, iPFK-2, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase, 6PF-2-K/Fru-2,6-P2ase 3, 6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme, PFK/FBPase 3, fructose-6-phosphate,2-kinase/fructose-2, 6-bisphosphatase, inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, renal carcinoma antigen NY-REN-56
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ16875
  • Protein Name
    6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3
  • Scientific Description
    Boster Bio Anti-PFKFB3 Monoclonal Antibody catalog # M02382. Tested in WB, IHC, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
  • Storage Instruction
    -20°C
  • UNSPSC
    12352203

References

  • Zhao Q, Li J, Wu B, et al. Smart Biomimetic Nanocomposites Mediate Mitochondrial Outcome through Aerobic Glycolysis Reprogramming: A Promising Treatment for Lymphoma. ACS Appl Mater Interfaces. 2020,12(20):22687-22701. doi: 10.1021/acsami.0c05763
    Read this paper